bluuebunny/crossref_metadata_2025_split huggingface dataset:
MET exon 14 skipping in NSCLC: An unMET Indian need.
Authors: Batra Ullas , Nathany Shrinidhi , Sharma Mansi , Patel Amrith , Mehta Anurag , Mattoo Sakshi , Noronha Vanita , Prabhash Kumar 
Published: May 2024

e13537 Background: The approval of capmatinib and tepotinib, selective MET tyrosine kinase inhibitors (TKI), has further shifted the therapeutic paradigm of advanced NSCLC. MET exon 14 skipping (MET ex14) alteration is a complex mechanism, reported in ~3-4% cases of NSCLC. Controlled trials have reported remarkable outcomes of selective MET TKIs, however real world outcomes from this part of the world are currently lacking. Methods: This is a non-interventional study reporting real world outcomes of NSCLC with MET ex14 from two apex cancer centers of India. 49 eligible patients were recovered from the electronic medical record archives. All cases with MET ex14 were included irrespective of clinicopathologic characteristics and therapy offered. Statistical analysis was performed using R studio. Results: Clinical characteristics are shown (Table). Treatment patterns were heterogeneous across therapy lines and included chemotherapy, MET TKIs and immune checkpoint inhibitors. 42/49 patients opted for treatment; rest dropped out owing to economic restraints. 1st line TKI was offered to 14 patients, and chemotherapy to 28 patients. 1st line PFS of TKI treated was 11.9 months (95%CI:5.8-17.8) vs. 5.9months (95%CI: 3.9-16.8) (p<0.002*) for the chemotherapy treated cases (HR for TKI: 0.3295 (95%CI: 0.1630 to 0.6663). Presence of TP53 co-mutation and male gender and were factors affecting 1st line PFS (p<0.06) on multivariate analysis. 2nd line treatment was opted by 13/14 patients in TKI treated group of which 5 received sequential TKI, and 8 received chemotherapy and 22/28 in chemotherapy treated group (TKI: 14, chemotherapy: 8). PFS for 2nd line TKI was 7.7 months (95%CI: 2.8-14.8) vs 4.6 months (95%CI:2.1-9.8) for chemotherapy {HR for TKI: 0.3641 (95%CI: 0.1378 to 0.9616)} (p<0.04*). The dropout rate from 1st to 2nd line was 36% and 44% in subsequent line. 28 (57%) received MET TKI at any given point in disease course. Median OS for patients treated with 1st line TKI was not reached at study end (95%CI: 9.2-NR) and was 20.7 months (95%CI:18.1-36.1) for chemotherapy (p=0.3). One year and 2 year survival rates for 1st line TKI and Chemotherapy were 86%vs 73% and 47% vs 45%, respectively. Conclusions: This is the largest cohort from India reporting real world uptake of TKI therapy in MET ex14 altered NSCLC. There is a blaring disparity with respect to accessibility of drugs, as well as prevailing socioeconomic restraints. This study clearly depicts an unmet need for more global clinical trials for rare genomic alterations as well as patient access programs in this part of the world. [Table: see text]
Clinicians' experiences and perspectives of a web-based lung cancer referral pathway.
Authors: Otty Zulfiquer Ali , Sabesan Sabe S. , Larkins Sarah , Evans Rebecca , Brown Amy 
Published: May 2024

e13539 Background: Efficient and streamlined referral of patients with suspected lung cancer is an integral part of providing optimal care for these patients. There is emerging evidence that use of online care pathways, such as HealthPathways is associated with improved referral quality from primary care, more timely access to secondary care and standardization of clinical management decisions by general practitioners (GPs). The Townsville Lung Cancer Referral Pathway (TLCRP) is part of ' Townsville HealthPathways', which is the evidence-based clinical pathway portal used in the Townsville Hospital and Health service in northern Australia. This study aimed to explore the experiences and perspectives of clinicians about TLCRP. Methods: This was a descriptive qualitative study nested within a larger project evaluating TLCRP, utilising a broader implementation science framework. In-depth, semi-structured interviews of GPs and lung cancer specialists were conducted. An iterative, inductive thematic analysis of interview transcripts was undertaken to derive key codes and themes regarding participant experiences and perceptions. Results: Twenty interviews were conducted, 14 with GPs and six with specialists across disciplines of respiratory medicine, oncology, and cardiothoracic surgery. Of the GPs, 11 were practicing in the regional locality of Townsville and three practiced in surrounding rural areas. Interview analysis identified two major themes and several sub-themes (Table). Several enablers and barriers to implementing TLCRP were identified. Barriers to adaptation of TLCRP included lack of clinical time, resistance to changing referral patterns, lack of familiarity or experience with HealthPathways and technology issues. Enablers included clinical usefulness of TLCRP, support from HealthPathways implementing team, integration of TLCRP with the electronic referral system and positive feedback from specialists. Conclusions: Emerging themes from this study may be used to reduce the barriers and improve uptake of TLCRP and other health care pathways in the local health service. Improving the uptake of TLCRP may mean that more patients in our region experience a streamlined journey to more timely specialist lung cancer care and improved health outcomes. [Table: see text]
Factors associated with delays in receipt of neoadjuvant chemotherapy in patients with operable breast cancer.
Authors: Wooster Margaux , DeStephano David , Beauchemin Melissa , Wang Shikun , Hur Chin , Wright Jason Dennis , Hershman Dawn L. , Accordino Melissa Kate 
Published: May 2024

e13541 Background: Delays in neoadjuvant chemotherapy initiation (NACTI) after breast cancer (BC) diagnosis have been associated with worse outcomes. We evaluated incidence and predictors of delays of NACTI among high clinical risk patients treated with NACT on a national level. Methods: We conducted a retrospective cohort study using the National Cancer Database. Eligibility included age ≥18 years, diagnosis of non-metastatic BC between 1/1/2010 – 12/31/2020, who were treated with NACT within 180 days of diagnosis. Patients who received neoadjuvant endocrine therapy were excluded. Time to chemotherapy (TTC) in days was recorded. Patients were categorized into sub-cohorts by receptor status and clinical stage: 1) Hormone Receptor positive/HER-2 negative (HR+/HER2-) and were lymph node (LN) LN+; 2) HER-2 positive (HER2+) cT2+ or LN+; and 3) triple negative BC (TNBC) cT2+ or LN+. Multivariable logistic regression, adjusted for demographic, socioeconomic and tumor characteristics, was used to identify characteristics associated with delays > 60 days from diagnosis to NACTI. Multiple imputation was used for missing data. Results: We identified 145,697 eligible patients, 74% were White, 18% were Black, 3.3% were Asian, and 4.6% were Other/Unknown. Across all racial categories, 9.2% were Hispanic. Median age at diagnosis was 52 years (range 18-90), median TTC was 32 days (range 0-180), and 10% had a delay > 60 days. There were 40,345 patients in the HR+/HER2- cohort, 56,868 in the HER2+ cohort, and 48,484 in the TNBC cohort; 12%, 9.0%, and 8.9% (p <0.001) had a delay in NACTI, respectively. In multivariable analysis among the HR+/HER2- sub-cohort, characteristics associated with delays in NACTI included Black race (OR 1.71, 95%CI 1.57-1.86) and Hispanic ethnicity (OR 1.76, 95%CI 1.60-1.94) compared to White and non-Hispanic patients. Patients with Medicare, Medicaid, or who were uninsured were more likely to be delayed (OR 1.44 95%CI 1.30-1.58, 2.10, 95%CI 1.92-2.29, 2.28, 95%CI 1.99-2.61) compared to those with commercial insurance. Results were similar in the HER2+ and TNBC cohorts, as seen in Table. Conclusions: Among patients with operable BC who received NACT, patients who were Black, Hispanic, had Medicaid or no insurance had as high as a twofold increase in odds of a delay in NACTI. Targeted interventions to address these racial and socioeconomic disparities are necessary to ensure equitable care. Multivariable logistic regression adjusted for demographic, socioeconomic and tumor characteristics variables (n= 145,697). [Table: see text]
Greening Ireland’s oncology practice: Reducing climate toxicity and improving sustainability in a national chemotherapy formulary.
Authors: Lynch Emer , Bredin Philip Hugh , Weadick Catherine , Barry Simon L , Dorney Niamh , Hamid Munzir , Hennessy Maeve , Myo Oo Nay , Bryan Alex J. , Cooke Katie , O'Mahony Deirdre , van Leeuwen Roelof W.F. , Van De Poll Matthijs , Collins Dearbhaile Catherine , O'Reilly Seamus 
Published: May 2024

e13557 Background: Climate change has been acknowledged by the World Health Organisation (WHO) as a “fundamental threat” to healthcare delivery. However, healthcare now accounts for more than 5% of global emissions. Over 25% of the oncology services contribution to this relates to the development, transport and administration of systemic anticancer therapies (SACT), and represents a modifiable factor. In Ireland, the National Cancer Control Programme (NCCP) determines the standard of care systemic anticancer therapy (SACT) protocols. This study proposes to review existing protocols and assess for and highlight nationally implementable climate toxicity mitigation strategies. Methods: NCCP SACT protocols (available at https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/) were reviewed for impact reduction potential under the following headings: 1) Baseline and regular tests and investigations; 2) Pre-medications; 3) De-escalation, and 4) ESMO Magnitude of Clinical Benefit. Results: A total of N = 333 protocols were reviewed. N = 32 protocols had multiple indications across more than one tumour stream. Overall, N = 702 opportunities were identified where the protocol impact could be reduced, either by consolidation of pre-medication and pre-hydration to oral administration, regimen or investigation de-escalation, dose banding, switching non-oral to equivalent oral SACT alternative or re-considering regimen use where clinical benefit is measured as non-substantial. In addition, there were a further N = 507 opportunities identified where baseline and regular investigations required by the protocol could be incorporated into routine visits, minimising hospital travel and time toxicity to patients. Conclusions: This study considered just one aspect of oncology care in Ireland, the delivery of SACT, and identified over 1200 opportunities across standardised national protocols where associated climate toxicity could be reduced without compromising standard of care. A sustainability matrix to promote identified action points is proposed for inclusion within all protocols and could be used in other jurisdictions. Further work to consider impact reduction opportunities in other areas of cancer care, including radiology and diagnostics should be considered.
Representativeness of race, ethnicity and social determinants of health in patients with advanced non-small cell lung cancer via linkage of real-world electronic health records, administrative claims, and consumer financial data.
Authors: Calip Gregory Sampang , Choi Yookyung Christy , Cai Mona , Liede Alexander , Monegro Natalie , McNeill Annie 
Published: May 2024

e13559 Background: Social determinants of health (SDOH) are both drivers of health disparities and barriers to clinical research participation, particularly among historically underserved or marginalized populations. Using real-world data (RWD), diversity plans in cancer clinical trials frequently aim to reduce disparities and improve representation. Our aim was to describe the representativeness of patients with advanced non-small cell lung cancer (aNSCLC) with respect to race, ethnicity and person-level SDOH in a curated electronic health record (EHR) database. Methods: This was a retrospective cohort study of individuals diagnosed with aNSCLC between 2016–2022 in a US-based oncology EHR database (ConcertAI). Information on person-level SDOH was derived from linkage of curated EHR data to administrative claims and consumer financial data. These data were also compared to a sample of patients diagnosed with first primary NSCLC from the Surveillance, Epidemiology, and End Results (SEER) Program and American Community Survey (ACS), where possible. The Kaplan-Meier product limit estimator was used to compare time from advanced diagnosis to treatment initiation. Results: From an overall sample of 17,772 patients with aNSCLC, a total of 10,390 patients had 1 or more SDOH characteristics of interest documented. Compared with patients without linked SDOH data, a higher proportion of patients with linked person-level SDOH data were non-Hispanic (NH) White patients (79% vs 71%) and lower proportions were NH Black (10% vs 13%), NH Asian/Pacific Islander (2% vs 4%) and Hispanic patients (2% vs 4%). Patients with linked SDOH were also more likely to have aNSCLC progressed from an earlier stage and received biomarker testing for targetable alterations. Overall, 54% of patients were married, 38% completed a bachelor’s degree or higher, 14% worked in a blue-collar occupation, and 61% had an individual income of ≤$35,000. All 4 of these SDOH characteristics differed significantly by race/ethnicity. Differences in time-to-treatment initiation were statistically significant by marital status (median of 50 [married] vs 55 [not married] days; P=0.02) and individual income (median of 50 [>$60,000] vs 55 [≤$30,000] days; P=0.04). Patients with aNSCLC in these data differed from patients in SEER and ACS estimates with respect to greater representation of patients who are NH White, have lower levels of education, and lower individual income. Conclusions: This analysis demonstrated the feasibility of measuring person-level SDOH using EHR from patients with aNSCLC treated at oncology clinics across the US. RWD with linked SDOH characteristics should be used cautiously to address the representativeness gap in evidence from oncology trials given their potential inherent selection biases.
Optimizing clinical research in a regional cancer center network: A survey-based approach.
Authors: Preeshagul Isabel Ruth , Syldor Angemael , Terzulli Stephanie Lucia , Gordon Ruth Ann , Evans Lauren A , Moran Solange , Eng Juliana , Daly Robert Michael , Rao Devika , Momtaz Parisa , Brockway Julia P , Joshi Smita Suhas , Houston Collette , Riely Gregory J. , Reidy Diane Lauren 
Published: May 2024

e13560 Background: Conducting clinical research (CR) within regional care networks (RCNs) of comprehensive cancer centers presents unique challenges. This study aimed to identify and address such barriers at Memorial Sloan Kettering Cancer Center's (MSKCC) RCN, encompassing six sites across New York and New Jersey. Methods: A survey was conducted among medical oncologists at the RCN sites (February 2022-February 2023) to assess their perspectives on research-related challenges. The 23-question survey included multiple-choice, open-ended, and ranking questions regarding protocol availability, consenting processes, staffing support, and more. Results: 92/108 (85%) medical oncologists completed the survey, revealing three key challenges: 1. Limited protocol availability: Only 47% of the time was there a suitable trial available in the RCN for patients interested in clinical trials. Notably, 50% of attendings referred over 5 patients out of the RCN to MSKCC Main Campus for trial enrollment. Identified barriers to opening desired protocols (n=23 in total) included closed to accrual, pending amendments, and sponsor approval issues. 2. Inadequate investigator representation: 278 protocols lacked RCN physicians listed as consenting providers hindering potential patient participation. 3. Insufficient research staff including clinical trial nurses and administrative staff. Only 33% were satisfied with the research support, and 67% of physicians identified lack of clinical research support staff as the biggest barrier to accrual. 58% reported delays of more than one week in screening eligible patients due to insufficient support. Following these observations, interventions were implemented. Thirteen of the 23 studies were opened to accrual, all RCN physicians were added to the 278 protocols, and an analysis of staffing needs increased clinical trial nursing and administrative staff. Therapeutic and non-therapeutic accruals in the Department of Medicine rose by 10.5%, and total research visits increased by 21.4% compared to the previous year. Conclusions: This survey-based approach identified and addressed key barriers to CR within MSKCC's RCN, and in turn, increased research activity was noted. These findings offer a potential roadmap for optimizing research in similar networks by enhancing protocol accessibility, addressing staffing needs, and fostering collaboration. Further investigations are ongoing to address challenges in other clinical departments.
Effect of alternative dosing strategies on sustainable healthcare: A carbon footprint analysis of nivolumab and pembrolizumab treatment in the Netherlands.
Authors: Malmberg Ruben , Loosveld Jurrien , Schilte Hans-Peter , van Leeuwen Roelof W.F. , Burdorf Alex 
Published: May 2024

e13564 Background: Hospitals contribute significantly to greenhouse gas (GHG) emissions and face a moral obligation to prioritize reduction of GHG emissions. Drugs constitute an important component of the GHG emissions of hospitals. Alternative dosing strategies (ADS) have been implemented to improve the cost-effectiveness of pembrolizumab and nivolumab (Table). However, the impact of these ADS on GHG emissions remains unknown. Therefore, this study aimed to analyse the effect of ADS implementation on the carbon footprint of treatment with pembrolizumab and nivolumab. Methods: Life Cycle Assessment (LCA) methodology was used to quantify the environmental impact. The impact category climate change was used to quantify the carbon emissions (CO2e). The GHG Protocol was used to categorize the emissions into scopes 1, 2 and 3. Life Cycle Inventory and Impact data from an academic hospital in Rotterdam were used in the LCA to calculate the CO2e for pembrolizumab and nivolumab, their different dosing intervals, and the impact of ADS. Results: In 2022, the carbon emissions related to nivolumab and pembrolizumab treatment were 445 tons CO2e, with an average of 94 kg CO2e per dosage. Pharmaceutical production was the main driver of treatment-related GHG emissions (93% of total emissions on average). Applying ADS, resulted in carbon emission reductions of 21.4-26.2% and 9.3-11.2% for pembrolizumab and nivolumab respectively (table 1). Conclusions: This study shows the substantial environmental impact of cancer treatments with pembrolizumab and nivolumab and calls for further implementation of ADS for pembrolizumab and nivolumab and other anti-PD-(L)1 monoclonal antibodies and more sustainable pharmaceutical production processes. These findings help to create environmental awareness and contribute to the promotion and understanding of sustainable low-carbon healthcare practices. Overview of registered doses of pembrolizumab and nivolumab, alternative dosing strategies and potential reductions in GHG emissions, based on real world data in The Erasmus University Medical Center in Rotterdam, the Netherlands. [Table: see text]
Assessing the landscape of integrative oncology at US comprehensive cancer centers (CCC).
Authors: Kim Elyssa , Cheng Jessica , Fertal Jamie , Munoz Frank , Saritoprak Seyma , Truong Amy , DiCristofano Christy , Ku Sarah , Rodriguez Art , Soni Preeti , Reb Anne Marie , Rose Judy , Lee Richard T. 
Published: May 2024

e13565 Background: Interest in integrative oncology (IO) has grown among patients and its availability has expanded within CCCs. This study assesses the availability of IO programs in U.S. CCCs. Methods: In 2023, a cross-sectional survey was sent to CCCs including NCI-designated CCCs by email regarding IO programs. Participants were asked to describe the importance of IO within their cancer center, the programs and services offered, and how the programs are provided. Results: Of ninety-four survey invitations sent, fifty-eight completed surveys were returned (response rate 62%). Three-fourths of completed surveys (74%) came from NCI-designated CCCs. Over half of respondents (57%) rated IO services to be important (or very important) at their center with 53% stating that their center has a formal IO clinical program. Univariate analysis showed that non-NCI centers were more likely to perceive IO services as being important compared to NCI-designated centers (100% vs. 77%, p=0.04). Respondents stated that their IO program has been in existence for ≥10 years (40%), 5-9 years (26%), and 0-4 years (34%). Among the surveyed cancer centers, availability of IO program was 33% (adult and pediatric) vs. 49% (adult only). The IO programs are available to patients with active cancer (91%), patients in survivorship off-treatment (81%), and healthy patients without a history of cancer (22%). The IO services were offered in an outpatient clinic on the main campus (76%), community sites (29%), or inpatient settings (40%). The most common oncology specific services reported were nutrition (51%), exercise counseling (42%), mind-body medicine (38%), and acupuncture (33%). The clinicians who provided integrative medicine consultations were primarily in internal medicine (31%), family medicine (26%), and medical oncology (19%). In inpatient and outpatient settings, insurance was billed for physical therapy (50% vs. 67%) and diet/nutrition (36% vs. 50%) services, whereas acupuncture (47%) and massage (43%) services were charged by cash/card in an outpatient setting only. Music therapy (33% vs. 47%) and pet therapy (34% vs. 43%) services were offered for free most commonly in both inpatient and outpatient settings, respectively. The highest average out of pocket fee service was acupuncture ($42±27) followed by integrative medicine consultations ($34±29). Conclusions: Despite increasing patient interest and established benefits of integrative therapies as noted by recently published ASCO clinical guidelines, only half of CCCs reported having a formal IO program. More research is needed to understand the gap between patient interest, the growing evidence-base, and how to expand integrative oncology services within existing cancer centers.